Rehabilitation for COPD patients

Kearney, Sarah
February 2010
Independent Nurse;2/1/2010, p40
The article focuses on the importance of pulmonary rehabilitation to patients suffering from chronic obstructive pulmonary disease (COPD). COPD refers to the condition that is commonly experienced by people who experience airflow obstruction after they have been diagnosed with emphysema or chronic bronchitis. It offers information on the enhanced pulmonary rehabilitation programme developed by the Isle of Wight Primary Care Trust's (PCT) COPD team in England.


Related Articles

  • Drugs in Clinical Development for Chronic Obstructive Pulmonary Disease.  // Pharmaceutical Medicine - New Zealand;2011, Vol. 25 Issue 4, p251 

    The article discusses advances in the pharmacotherapy of chronic obstructive pulmonary disease (COPD). It cites bronchitis, emphysema and mucus hypersecretion as conditions underlying COPD. Treatment options for suppressing pulmonary inflammation in COPD are roflumilast and protease inhibition....

  • Surgical approaches for lung volume reduction in emphysema. CRAWFORD, EMMA; SRINIVASAN, KOOTTALAI; MOUDGIL, HARMESH; NAICKER, THIRUMALAIRENGARAJAN; AHMAD, NAWAID // Clinical Medicine;Oct2014, Vol. 14 Issue 5, p558 

    A letter to the editor is presented in response to the article related to lung volume reduction surgery (LVRS) by S. J. Clark and others in the December 10, 2013 issue.

  • Fluticasone and Vilanterol Oral Inhalation.  // AHFS Consumer Medication Information;Apr2019, p1 

    The combination of fluticasone and vilanterol is used to control wheezing, shortness of breath, coughing, and chest tightness caused by chronic obstructive pulmonary (COPD; a group of diseases that affect the lungs and airways, that includes chronic bronchitis and emphysema). Fluticasone is in a...

  • RESPIRATORY TRACT.  // Nurse Practitioners Prescribing Reference;Winter2009/2010, Vol. 16 Issue 4, p257 

    The article offers information on prescriptions of various drugs to treat respiratory tract disorders. Advair Diskus from GlaxoSmithKline is used to maintain treatment of asthma in patients who are not adequately controlled on other asthma-controller medications. Combivent from Boehringer...

  • Helping the Chronically Short of Breath. Roper, Jenevieve; Kravitz, Len // IDEA Fitness Journal;Jun2013, Vol. 10 Issue 6, p20 

    The article focuses on the new way of exercise that helps people with emphysema, chronic bronchitis and other ailments that is caused due to chronic obstructive pulmonary disease (COPD). It mentions that people with COPD have trouble in exercising still they should be encouraged to carry out...

  • Chronic obstructive pulmonary disease: insidious, debilitating and costly. Chapman, John // Australian Journal of Pharmacy;May2013, Vol. 94 Issue 1116, p78 

    The article discusses the pathophysiology, symptoms and treatment of chronic obstructive pulmonary disease (COPD). It mentions the differences between emphysema and chronic bronchitis, the risk factors of developing COPD including cigarette smoking, air pollution and impaired lung growth and a...

  • COPD Management: Look Beyond the Airway Obstruction, Chronic Bronchitis and Emphysema. Ghamande, Shekhar A.; Dedhia, Harakh V. // Current Respiratory Medicine Reviews;2011, Vol. 7 Issue 1, p61 

    Chronic medical conditions occur in more than half of the patients with COPD. They contribute to COPD-related hospitalizations and they have been shown to prolong length of stay in patients with COPD. The presence of COPD can adversely impacts patients admitted to hospital with other conditions...

  • Olodaterol: Once-daily inhalation spray for COPD. YOUNG, CARA ALDRIDGE // Pharmacy Today;Sep2014, Vol. 20 Issue 9, p36 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) for olodaterol, a once-daily inhalation spray for the treatment of airflow obstruction in patients with chronic obstructive pulmonary diseases including chronic bronchitis and emphysema. It states that the...

  • Today's Headline: Safety Profile for GSK's Combination COPD Therapy Problematic.  // BioWorld Today;9/11/2013, Vol. 24 Issue 174, p15 

    The article reports that the U.S. Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee unanimously supported the efficacy data for new drug application 203975 for umeclidinium and vilanterol powder for inhalation while expressing reservations on the products' safety. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics